A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors

Go Back to All Clinical Trials

A Phase 1a/1b Trial of LY3962673 in Participants with KRAS G12D-Mutant Solid Tumors

Brief description of study

This study is testing the tolerability, effectiveness, and potential for few side effects of the drug LY3962673 in patients with advanced solid tumors that have a KRAS G12D mutation, like pancreatic, colorectal, and lung cancer. In Phase 1a, the drug will be tested alone to see if it is well-tolerated and has few side effects. Some patients may receive different doses to check for side effects and how the drug works in the body. In Phase 1b, LY3962673 will be tested alone and with other standard treatments to find the best dose for these cancers. A committee will decide on dose increases based on the safety data.

Clinical Study Identifier: s24-00561

ClinicalTrials.gov Identifier: NCT06586515

Principal Investigator: Paul E. Oberstein.

Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Samantha VanMaanen, Douglas K Marks, Jessica Wang, Kathleen M Madden, Elaine Shum, Salman Rafi Punekar, Kristen Spencer, Scot Niglio, Keriann M Scavone, Nina Beri, Nancy Chan, Maya Dimitrova, Kirby Rodriguez, Eneil De La Pena, Janice Mehnert, David R. Wise.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies